New levodopa therapeutic strategies

Parkinsonism and Related Disorders

Volumn 22, Issue , 2016, Pages S37-S40

  LeWitt, Peter A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug delivery; Levodopa; Parkinson disease; Pharmacotherapy

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOPAMINE; LEVODOPA; ANTIPARKINSON AGENT; DRUG COMBINATION;

ARTICLE; CLINICAL FEATURE; CLINICAL RESEARCH; DOPAMINE BLOOD LEVEL; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG DELIVERY SYSTEM; HIPPOCAMPAL CA1 REGION; HUMAN; NERVE CONDUCTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; ANIMAL; DRUG COMBINATION; METABOLISM; PARENTERAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; TRENDS;

ANIMALS; ANTIPARKINSON AGENTS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; HUMANS; INFUSIONS, PARENTERAL; INFUSIONS, SUBCUTANEOUS; LEVODOPA; PARKINSON DISEASE;

EID: 84947742323     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.09.021     Document Type: Article

References (26)

1. LeWitt P.A. Levodopa for the treatment of Parkinson's disease. N. Engl. J. Med. 2008, 359:2468-2476.
2. LeWitt P.A. The pharmacology of levodopa in treatment of Parkinson disease: an update. Handbook of Experimental Pharmacology 1989, vol. 88:325-384. Springer-Verlag, Berlin. D.B. Calne (Ed.).
3. Hornykiewicz O. A brief history of levodopa. J. Neurol. 2010, 257(Suppl 2):S249-S252.
4. Carlsson A., Lindqvist M., Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957, 180:1200.
5. Cotzias G.C., Van Woert M.H., Schiffer L.M. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 1967, 276:374-379.
6. Cotzias G.C., Papavasiliou P.S., Gellene R. Modification of Parkinsonism: chronic treatment with l-dopa. N. Engl. J. Med. 1969, 280:337-345.
7. Nutt J.G., Fellman J.H. Pharmacokinetics of levodopa. Clin. Neuropharmacol. 1984, 7:35-49.
8. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin. Pharmacokinet. 2006, 45:109-136.
9. LeWitt P.A. Levodopa therapy for Parkinson's disease: pharmacokinetics and pharmacodynamics. Mov. Disord. 2015, 30:64-72.
10. Anderson E., Nutt J. The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications. Park. Relat. Disord. 2011, 17:587-592.
11. Misu Y., Kitahama K., Goshima U. L-3,4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system. Pharmacol. Ther. 2003, 97:117-137.
12. Misu Y., Goshima Y. DOPA as a neurotransmitter candidate. Neurobiology of DOPA as a Neurotransmitter 2006, 23-34. CRC Press, Boca Raton, FL. Y. Misu, Y. Goshima (Eds.).
13. King J.M., Muthian G., Mackey V., Smith M., Charlton C. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease. Life Sci. 2011, 89:638-643.
14. Newcomer T.A., Rosenberg P.A., Aizenman E. Iron-mediated oxidation of 3,4-dihydroxyphenylalanine to an excitotoxin. J. Neurochem. 1995, 64:1742-1748.
15. Guatteo E., Yee A., McKearney J., et al. Dual effects of L-DOPA on nigral dopaminergic neurons. Exp. Neurol. 2013, 247:582-594.
16. Aureli C., Cassano T., Masci A., et al. 5-S-cysteinyldopamine neurotoxicity: influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease. J. Neurosci. Res. 2014, 92:347-358.
17. LeWitt P.A., Jennings D., Lyons K.E., et al. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. Mov. Disord. 2009, 24:1319-1324.
18. Hsu A., Yao H.M., Gupta S., Modi N.B. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet), sustained-release carbidopa-levodopa (Sinemet CR), and carbidopa-levodopa-entacapone (Stalevo). J. Clin. Pharmacol. 2015, 55:995-1003.
19. Hauser R.A., Hsu A., Kell S., et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013, 12:346-356.
20. Olanow C.W., Kieburtz K., Odin P., Espay A.J., Standaert D.G., Fernandez H.H., Vanagunas A., Othman A.A., Widnell K.L., Robieson W.Z., Pritchett Y., Chatamra K., Benesh J., Lenz R.A., Antonini A. LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014, 13:141-149.
21. Verhagen Metman L., Stover N., Chen C., Cowles V.E., Sweeney M. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease. Mov. Disord. 2015, 10.1002/mds.26219.
22. Chen C., Cowles V.E., Sweeney M., Stolyarov I.D., Illarioshkin S.N. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. Clin. Neuropharmacol. 2012, 35:67-72.
23. LeWitt P.A., Giladi N., Gurevich T., et al. Accordion Pill carbidopa/levodopa (AP CD/LD) for treatment of advanced Parkinson's disease (PD). Mov. Disord. 2014, 29(suppl 1):S248.
24. LeWitt P.A., Huff F.J., Hauser R., et al. Double-blind study of an actively-transported levodopa prodrug, XP21279, in Parkinson disease. Mov. Disord. 2014, 29:75-82.
25. LeWitt P.A., Saint-Hilaire M.-H., Grosset D.G., et al. Inhaled levodopa (CVT-301) provides rapid improvement of OFF states in Parkinson's disease. Mov. Disord. 2015, 30:S99-S100.
26. Giladi N., Caraco Y., Gurevich T., Djaldetti R., Cohen Y., Yacobi-Zeevi O., Oren S. Pharmacokinetic profile of ND0612L (levodopa/carbidopa) for subcutaneous infusion) in patients with moderate to severe Parkinson's disease. Mov. Disord. 2015, 30(suppl 1):S87.